Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
92.74 CHF | +0.46% | +5.48% | +9.33% |
01:37pm | Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales | DJ |
05-10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.33% | 208B | |
+30.38% | 684B | |
+29.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+15.96% | 240B | |
-7.28% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Transcript : Novartis AG - Shareholder/Analyst Call